Ildong Pharmaceutical Co., Ltd. (249420.KS) Stock

249420.KS logo

Ildong Pharmaceutical Co., Ltd.

249420.KSSouth Korea
Healthcare

Company profile

Ildong Pharmaceutical reported revenue of 566.93 billion KRW for fiscal year 2025, down 7.8% from fiscal year 2024. In Q1 2026 (the quarter ended March 31, 2026) revenue was 142.00 billion KRW, up 4.4% from a year before. South Korea was its largest region in fiscal year 2025, with 98% of revenue. In Q1 2026 it reported net income of 8.27 billion KRW, against net income of 1.03 billion KRW a year earlier. Our analysis of its filings shows revenue shrinking from 600.76 billion KRW in fiscal year 2023 to 566.93 billion KRW in fiscal year 2025, 2.9% a year on average. Ildong Pharmaceutical reports about 1,050 full-time employees.

What stands out

  • It returned to a profit in fiscal year 2025, 27.66 billion KRW, after 4 years of net losses (4.58 billion KRW in fiscal year 2024).

Figures from company filings; latest fiscal year ended December 31, 2025.

About Ildong Pharmaceutical Co., Ltd.

Ildong Pharmaceutical Co., Ltd. develops, manufactures, and sells pharmaceutical products in South Korea. The company offers active lactic acid bacterial and anti-diarrheal agents, antibiotics, antifungal and antiviral products, anti-cancer, antineoplastic agents, and NSAIDs and analgesics, as well as vitamins, minerals, and nutrients; and drugs for blood circulation, cardiovascular and central nervous system, dental, endocrine and metabolic system, gastrointestinal system, respiratory system, and urogenital system applications. It also provides raw material drugs; health foods and foods; beverages; cosmetics; medical devices for scar treatment; and other drugs for treating thick wounds, osteoarthritis, periarthritis of shoulder, and artificial tears, as well as feminine cleanser products. The company was founded in 1941 and is headquartered in Seoul, South Korea.

Largest shareholders

  • Ildong Holdings Co., Ltd.30.52%
  • Won-Young Yoon1.968 %1.97%
  • Db Ildong Best Third Co. Ltd.1.27%
  • Woong-Sub Yoon1.223 %1.22%
  • IL DONG PHARMACEUTICAL CO Ltd0.41%

Share of the company, as of September 25, 2026

Leadership

  • Yun Paul Woongsup — CEO & Chairman

How much revenue does Ildong Pharmaceutical make?

Ildong Pharmaceutical reported 566.93 billion KRW in revenue for fiscal year 2025, down 7.8% from 614.94 billion KRW in fiscal year 2024. In Q1 2026 revenue was 142.00 billion KRW.

Where does Ildong Pharmaceutical make most of its revenue?

South Korea: 98% of revenue by region in fiscal year 2025, followed by Japan (1%).

What companies are similar to Ildong Pharmaceutical?

Listed companies of a similar size in the same industry (multi-therapeutic drug manufacturing) include Daewoong Co., Ltd. (003090.KS), JW Pharmaceutical Corporation (001060.KS), Shinpoong Pharmaceutical Co.,Ltd (019170.KS), Bukwang Pharmaceutical Co., Ltd. (003000.KS).

Has Ildong Pharmaceutical made a profit in recent years?

Net income by fiscal year: FY2021, a loss of 99.71 billion KRW; FY2022, a loss of 141.58 billion KRW; FY2023, a loss of 78.93 billion KRW; FY2024, a loss of 4.58 billion KRW; FY2025, 27.66 billion KRW. It reported a net loss in 4 of these 5 years.

Company Information

SectorHealthcare
IndustryMulti-Therapeutic Drug Manufacturing
Employees1,050
HeadquartersSeoul, South Korea
ExchangeKSE
TimezoneAsia/Seoul (KST)

Contact & Links

Address
2, Baumoe-ro 27-gil, Seoul, 137-130
Phone
82 2 526 3114
Disclaimer: This analysis is for informational and educational purposes only and does not constitute financial, investment, tax, or legal advice. Data may be incomplete, delayed, or contain inaccuracies. Consult with a qualified financial advisor before making any investment decisions.

Data as of .

How to cite: DataPorium, “Ildong Pharmaceutical Co., Ltd. (249420.KS)”, data as of Sep 25, 2026, https://dataporium.tech/stocks/249420.KS

LinkedInLinkedInXXYouTubeYouTube